Across borders and histologies: Rethinking endpoints for vascular sarcoma trials.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 41855129.
- Also identified by DOI 10.1158/1078-0432.CCR-26-0064.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Eribulin was evaluated in angiosarcoma and epithelioid hemangioendothelioma through two prospective international trials. While encouraging activity was observed in EHE, its role in angiosarcoma may depend on further refinement through subgroup selection. These findings underscore the importance of histology-specific interpretation, innovative endpoints, and coordinated strategies for ultra-rare sarcoma drug development.